Amgen Submits Supplemental NDA for Mild-to-Moderate Psoriasis Drug Otezla

Amgen has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for its adult mild-to-moderate plaque psoriasis treatment, Otezla® (apremilast), according to a statement released by the company today.